Matthew Metzger
Vice President, US Operations Oxford BioTherapeutics
Matthew joined Oxford Biotherapeutics in 2022 and has since been dedicated primarily to external innovation, coordinating and delivering target validation data for partnership programs and business development, developing content and strategies for future partnerships. Currently, he serves as the Alliance and Program Manager of the preclinical programs for both the Roche and Zymeworks collaborations. Additionally, he oversees the internal ADC and bispecific development pipeline. He completed grad school at UC Berkeley and brings years of experience in early-stage biotech startups.
Seminars
Thursday 10th September 2026
From Platform Potential to Deal Reality: Aligning Modality, Targets & Evidence
12:00 pm
- Integrating pan-cancer or broadly applicable targets while maintaining specificity, and using this to evidence a scalable, differentiated discovery engine without compromising safety
- How do we determine which targets align with a given modality’s safety, selectivity and therapeutic potential?
- Sharing experience demonstrating the validation of a credible platform, including evolution from platform narrative to an asset-led story
- Discussing types of deals possible for platforms versus assets, and what is the minimum evidence needed for a deal?
